A study to assess self-reported systemic side effects and flares in patients with rheumatic diseases who received one of the approved COVID-19 vaccines in Italy
Latest Information Update: 12 Jan 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 12 Jan 2022 New trial record